ENVALITH
キッズウェル・バイオ株式会社 logo

Kidswell Bio Corporation

4584・Growth Market・Pharmaceuticals

Official website
キッズウェル・バイオ株式会社 logo
Kidswell Bio Corporation4584

Business

Kidswell Bio Corporation is a biotech venture operating two businesses: the biosimilar business and the cell therapy business (regenerative medicine). In the biosimilar business, since 2012 the company has launched four products—filgrastim, darbepoetin alfa, ranibizumab, and pegfilgrastim—and secures sustainable revenue by supplying active pharmaceutical ingredients to partner pharmaceutical companies such as Fuji Pharma, Senju Pharmaceutical, and Mochida Pharmaceutical. In the cell therapy business, the wholly owned subsidiary S-Quatre leverages its proprietary deciduous tooth pulp stem cells (SQ-SHED) to advance clinical development, with cerebral palsy (chronic phase) as its top-priority indication. Under a virtual R&D framework, the company efficiently utilizes its limited management resources through collaboration with academia, CDMOs, and pharmaceutical companies.

Business Model

In the biosimilar business, the company generates revenue through two pillars: one-time income from development milestone payments and sales revenue from supplying APIs to partner pharmaceutical companies. In the cell therapy business, the company anticipates one-time contract payments, milestone revenue, SQ-SHED supply revenue, and royalty revenue upon partnering with pharmaceutical companies. The structure aims to achieve "a balance of stability and growth" by reinvesting the stable revenue generated by the biosimilar business, along with accumulated know-how, into R&D for the cell therapy business.

Company Strengths

Since 2012, the company has launched four products: filgrastim, darbepoetin alfa, ranibizumab, and pegfilgrastim. Among the 23 biosimilar products approved in Japan, it has been involved in the development of 4 products and the stable supply of 3 products, an achievement unparalleled among bio-ventures. GBS-001 and GBS-011 have achieved a replacement rate of over 80% from the original preceding products.

Rather than handling all processes in-house, the company has built a "virtual-style" R&D structure through collaboration with CDMOs, academia, and pharmaceutical companies. It begins discussions with candidate partner pharmaceutical companies from the early stages of development, establishing a flexible structure that can advance multiple projects in parallel while distributing development risk and cost burden.

Utilizing SQ-SHED (deciduous tooth pulp stem cells) independently developed by subsidiary S-Quatre, the company completed administration to all 3 cases in a joint clinical research study with Nagoya University. In October 2025, an independent safety evaluation committee assessed that there were "no safety concerns up to 4 weeks after administration," and interim analysis reported significant improvement in motor function. In January 2026, a joint research paper was published in a leading international academic journal.

ENVALITH's Perspective

Although the company achieved its first consolidated operating profit since listing (¥28 million) in FY2025 (ended March 2025), R&D expenses ballooned to ¥1,120 million in FY2026 (ending March 2026) (up ¥352 million year on year), pushing the company into an operating loss of ¥138 million. In addition, non-operating expenses such as a loss on disposal of inventories of ¥125 million and syndicated loan arrangement fees of ¥75 million compounded the situation, widening the ordinary loss to ¥374 million and the net loss attributable to owners of parent to ¥414 million. While the Biosimilar Business is said to have secured an operating profit on a standalone basis, the timing of achieving stable earnings on a consolidated basis remains unclear, and whether the company can return to operating profit in the following fiscal year (forecast range of ¥100 million to ¥600 million) will be a key focus.

In FY2026 (ending March 2026), sales to Senju Pharmaceutical amounted to ¥3,468 million (52.6% of the total), while sales to Mochida Pharmaceutical amounted to ¥2,240 million (34.0%), continuing a highly concentrated sales structure in which the top two customers account for over 86% of total sales. In particular, for GBS-007 (Ranibizumab), the mainstay product in the ophthalmology field, the competitive landscape is changing as an aflibercept biosimilar and bio-AG (authorized generic biologic) have received drug price listing and commenced sales. The company states that it is currently taking a conservative view on the outlook for GBS-007, and depending on prescribing trends for competing products, there is a possibility that downside risks to sales and profit could materialize.

Cash and cash equivalents at the end of FY2026 (ending March 2026) stood at ¥3,295 million, an increase of ¥299 million year on year, and short-term liquidity stabilized following the procurement of a ¥2,500 million syndicated loan. The company judges that there is no material uncertainty regarding the going concern assumption. On the other hand, dilution from the continued conversion of convertible bonds with stock acquisition rights (balance of ¥125 million) and the exercise of stock acquisition rights (¥310 million in stock issuance proceeds for the current period) continues, with the number of shares issued increasing by 5,742 thousand shares year on year to 49,623 thousand shares. The possibility of additional fundraising associated with increased clinical development expenses in the Cell Therapy Business remains, and concerns over dilution have not been dispelled.

Growth Strategy

Four pillars: improving profitability of existing biosimilars, developing new biosimilar products, establishing domestic manufacturing facilities, and advancing regenerative medicine clinical progress

Promoting supply price revisions and switching to lower-cost manufacturing methods, primarily for GBS-007 and GBS-010. Some measures were already implemented during FY2026 (ending March 2026), and the following fiscal year is expected to see improved profit margins from their full-year contribution. Price negotiations with partner companies continue in response to yen depreciation and rising overseas prices.

In May 2025, entered into a Master Service Agreement with MBI and began cell line construction for multiple candidate products. In October of the same year, entered into a basic memorandum of understanding and basic agreement among the three parties, adding Alfresa Holdings. Under the contract structure, consideration is received from Alfresa Holdings according to the progress of cell line construction, and a portion was already recorded as revenue in FY2026 (ending March 2026).

Selected for the Ministry of Health, Labour and Welfare's support program for establishing domestic biosimilar manufacturing facilities (May 2025). In November 2025, established the joint venture "Alfenax Biologics Corporation" with four companies—Alfresa Holdings, Chiome Bioscience, and MBI—and began construction of a manufacturing facility on the premises of Alfresa Fine Chemical. Aims to establish a medium- to long-term domestic manufacturing and revenue base.

Domestically: The clinical research on autologous SQ-SHED led by Nagoya University (administration completed for all three cases, safety confirmed, interim analysis published), and preparations for a domestic clinical trial of GCT-103 (GMP manufacturing preparations underway) through co-commercialization with Mochida Pharmaceutical. Overseas: Completion of a Pre-IND Meeting with the U.S. FDA and progress toward an IND application in collaboration with Treehill Partners. In March 2026, the R&D structure was reorganized to concentrate management resources on cerebral palsy.

Last updated: July 19, 2026